SOURCE: Medistem Laboratories, Inc.

January 24, 2007 08:00 ET

Medistem Laboratories Announces Plan for Angiostem™ to Be First Pipeline Product for U.S. Commercialization

Product Aims to Induce Formation of New Blood Vessels, Providing New Method of Treatment for Cardiovascular, Critical Limb Ischemia, and Other Diseases

SCOTTSDALE, AZ -- (MARKET WIRE) -- January 24, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U), announced today it has filed a patent application covering its Angiostem™ platform, a technology with potential to benefit cardiac and limb ischemic diseases. Angiostem™ is planned to be the company's first pipeline product intended for U.S. commercialization.

If approved for human use, the Angiostem™ platform will allow for the manipulation of cord blood so as to enable it to be used by different individuals without the need for immune suppression. Numerous studies in animals have demonstrated that cord blood stem cells are capable of potently generating new blood vessels in tissue lacking oxygen, preventing tissue dysfunction or death. These studies have shown that cord blood stem cells benefit animal models of cardiac ischemia, limb ischemia, as well as various liver diseases. Unfortunately, the need for immune suppression has prevented treatment application to humans. If successful in human trials, the Angiostem™ technology will provide a therapeutic benefit for numerous diseases associated with poor circulation, including critical limb ischemia; a disease that causes approximately 150,000 amputations per year in the U.S. and Europe.

"The clinical use of cord blood stem cell therapy in the U.S. is currently limited due to the perceived need to suppress the recipient's immune system. While this approach is ethically acceptable in cancer due to lack of alternative treatments, such therapy for diseases ranging from heart failure to limb ischemia to liver cirrhosis is not currently used since immune suppression alone carries a high risk of adverse effects," said Neil Riordan, CEO of Medistem. "We are hopeful the Angiostem™ therapeutic platform will provide new treatment options for patients with critical limb ischemia, and other diseases that require new blood vessel generation."

Medistem is currently in discussions with several academic institutions for completion of pre-clinical studies so as to enable an Investigational New Drug (IND) filing with the FDA in the second half of 2007. If accepted by the FDA, the company will move to begin U.S. clinical trials. Medistem has also submitted a publication in a peer-reviewed journal describing the scientific basis for cord blood transplantation in absence of immune suppression.

About Critical Limb Ischemia

In the U.S. alone, it is estimated that approximately 750,000 people suffer from critical limb ischemia. The disease is characterized by a narrowing and hardening of the arteries, typically affecting the legs and feet. With decreased blood flow, patients can suffer a host of symptoms, including nerve injury and tissue damage. In advanced stages, limb ischemia can lead to gangrene and severe tissue damage, often requiring amputation of the affected limb. Limb ischemia is associated with a high rate of mortality and the need for frequent hospitalization from surgical complications. With no real alternatives outside of surgery currently available, there is a definite need for techniques that induce formation of new blood vessels in the patient without the use of invasive techniques.

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help patients while seeking to commercialize products in the U.S. market. Clinic treatments use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for the treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Medistem Laboratories, Inc.
    Chris McGuinn
    Email Contact